Literature DB >> 3044434

Does chemotherapy improve survival in advanced breast cancer? A statistical overview.

R P A'Hern1, S R Ebbs, M B Baum.   

Abstract

The relative efficacies of cytotoxic chemotherapy regimens in the treatment of advanced breast cancer are generally assessed by comparing response rates in randomised trials. Treatment attempts to prolong survival but trials rarely demonstrate a statistically significant survival advantage: it has been argued that chemotherapy does not prolong survival. The correlation between response rates and survival has been examined by reviewing 79 comparisons between arms with unequal response rates in 50 published trials of chemotherapy in advanced breast cancer. In 73% of comparisons the group with the higher response rate also demonstrated the longer median survival (P less than 0.001). Weighted linear regression showed a statistically significant relationship between relative response rates and survival (P less than 0.001). The number of patients in a comparison did not influence this relationship.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044434      PMCID: PMC2246459          DOI: 10.1038/bjc.1988.140

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  Results of treatment of carcinoma of the breast.

Authors:  D BRINKLEY; J L HAYBITTLE
Journal:  Lancet       Date:  1959-01-10       Impact factor: 79.321

2.  Prognosis in inoperable stage III carcinoma of the breast.

Authors:  R D Rubens; P Armitage; P J Winter; D Tong; J L Hayward
Journal:  Eur J Cancer       Date:  1977-08       Impact factor: 9.162

3.  Treatment and survival on advanced breast cancer.

Authors:  T Priestman; M Baum; V Jones; J Forbes
Journal:  Br Med J       Date:  1978-12-16

4.  Improved survival of patients with metastatic breast cancer receiving combination chemotherapy.

Authors:  M B Ross; A U Buzdar; T L Smith; N Eckles; G N Hortobagyi; G R Blumenschein; E J Freireich; E A Gehan
Journal:  Cancer       Date:  1985-01-15       Impact factor: 6.860

5.  Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials.

Authors:  T C Chalmers; H Levin; H S Sacks; D Reitman; J Berrier; R Nagalingam
Journal:  Stat Med       Date:  1987 Apr-May       Impact factor: 2.373

6.  Effect of current palliative treatment on the survival of patients with breast cancer.

Authors:  J E Devitt; D A Advent
Journal:  Can J Surg       Date:  1977-01       Impact factor: 2.089

7.  Response and survival in advanced breast cancer after two non-cross-resistant combinations.

Authors:  C Brambilla; M De Lena; A Rossi; P Valagussa; G Bonadonna
Journal:  Br Med J       Date:  1976-04-03

8.  Does more intense palliative treatment improve overall survival in metastatic breast cancer patients?

Authors:  J K Patel; T Nemoto; M Vezeridis; N Petrelli; O Suh; T L Dao
Journal:  Cancer       Date:  1986-02-01       Impact factor: 6.860

9.  Effect of chemotherapy on survival in metastatic breast cancer.

Authors:  A H Paterson; O Szafran; F Cornish; A W Lees; J Hanson
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

10.  Long-term survival of patients with breast cancer: a study of the curability of the disease.

Authors:  A O Langlands; S J Pocock; G R Kerr; S M Gore
Journal:  Br Med J       Date:  1979-11-17
View more
  18 in total

1.  Primary medical treatment in breast cancer.

Authors:  Z Rayter; R F Phipps
Journal:  BMJ       Date:  1991-01-05

Review 2.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

Review 3.  Is there a growing role for endocrine therapy in the treatment of breast cancer?

Authors:  P E Lønning
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

4.  Progression-free survival as a surrogate endpoint in advanced breast cancer.

Authors:  Rebecca A Miksad; Vera Zietemann; Raffaella Gothe; Ruth Schwarzer; Annette Conrads-Frank; Petra Schnell-Inderst; Björn Stollenwerk; Uwe Siebert
Journal:  Int J Technol Assess Health Care       Date:  2008       Impact factor: 2.188

5.  Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer.

Authors:  Kimberly S Chiew; Heather Shepherd; Janette Vardy; Martin H N Tattersall; Phyllis N Butow; Natasha B Leighl
Journal:  Health Expect       Date:  2008-03       Impact factor: 3.377

Review 6.  Postmenopausal breast cancer. Drug therapy in the 1990s.

Authors:  C I Falkson; G Falkson; H C Falkson
Journal:  Drugs Aging       Date:  1993 Mar-Apr       Impact factor: 3.923

Review 7.  Management of metastatic breast cancer.

Authors:  K Wong; I C Henderson
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

8.  Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.

Authors:  John R Goffin; Greg R Pond
Journal:  BMC Med Res Methodol       Date:  2011-12-12       Impact factor: 4.615

9.  Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.

Authors:  S C Fraser; H J Dobbs; S R Ebbs; L J Fallowfield; T Bates; M Baum
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

10.  Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.

Authors:  R P A'Hern; I E Smith; S R Ebbs
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.